Zymeworks and BeOne: Long‑Term Cancer Study Update Supports Durable Drug Story
Zymeworks (ZYME), BeOne Medicines (ONC) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
The long‑term extension study NCT04164199 tracks how patients do over time on a group of cancer drugs from BeOne Medicines and partners, including Zymeworks’ zanidatamab (ZYME). The study follows people with advanced cancers who were already treated in earlier trials, and it focuses on long‑run safety, durability of benefit, and how feasible chronic treatment may be in real‑world settings.
The study tests a wide mix of immunotherapy and targeted drugs, alone and in combinations. Key agents include tislelizumab, pamiparib, sitravatinib, and Zymeworks’ zanidatamab, with some arms pairing these with other medicines to see whether combinations can extend control of disease or improve tolerability versus single‑drug use.
This is an interventional Phase 3 extension study with no randomization, so doctors assign patients to treatment arms instead of using a lottery. It is open label, meaning everyone knows which drug is being given, and the core goal is treatment: to keep cancer in check while tracking side effects and how long responses last after earlier trials end.
The trial was first submitted on 14 Nov 2019, marking the start of enrollment planning and site setup. The record was last updated on 2 Jun 2026, showing that follow‑up, data cleaning, and integration of long‑term outcomes remain active even though the overall trial status is now listed as completed.
For investors in Zymeworks (ZYME) and BeOne’s oncology platform, this update supports the story that core assets like zanidatamab and tislelizumab can be used safely over longer periods, which matters for pricing power and eventual usage in later‑line settings. With crowded competition in immuno‑oncology and targeted therapies, solid long‑term safety and persistence data can be a quiet but important edge that supports valuations and partnerships rather than a near‑term trading catalyst.
This extension study has been updated on the ClinicalTrials portal, and while listed as completed, ongoing data maintenance confirms that further details and analyses remain available there.
To learn more about ZYME’s potential, visit the Zymeworks drug pipeline page.
